GLP-1 receptor agonists reduce obesity-related surgical risks by 10–20% body weight loss and improve metabolic health before hernia repair, but delayed gastric emptying raises anesthesia safety concerns that need careful perioperative management.
10–20%Body weight reduction achievable with GLP-1 receptor agonists before hernia surgery, reducing obesity-related surgical complications
What the researchers found
GLP-1 receptor agonists achieve 10–20% weight reduction and reduce perioperative complications in hernia patients, but the delayed gastric emptying they cause creates anesthesia safety challenges requiring individualized fasting protocols.
Why it matters
Hernia surgery in obese and diabetic patients has high complication rates that inflate healthcare costs and patient suffering. Preoperative optimization with GLP-1 drugs could make surgery safer and reduce recurrence—but only if gastric emptying risks are properly managed.
The numbers in context
- 20+ million hernia repairs performed annually worldwide
- GLP-1 drugs produced 10-20% weight reduction preoperatively
- GRIP/CRIP approach: 5-7% five-year recurrence vs 15% conventional
- Reduced surgical site infections, thromboembolic events, and wound dehiscence with GLP-1 pretreatment
How the study worked
Comprehensive narrative review incorporating recent clinical trials, observational studies, and meta-analyses on GLP-1 drugs, botulinum toxin A, progressive pneumoperitoneum, and biomechanical repair for hernia surgery.
Who was studied
Review covering obese and diabetic patients undergoing abdominal wall hernia repair, with focus on metabolic and mechanical prehabilitation strategies.
What this study cannot tell us
Narrative review subject to selection bias. No randomized trials specifically on GLP-1 drugs as hernia surgery prehabilitation. Optimal timing for stopping GLP-1 drugs before surgery is not established. Evidence on long-term hernia recurrence with preoperative GLP-1 use is lacking.
How to read the evidence
Rated moderate: narrative review drawing on a mix of RCT and observational evidence; no direct RCT of GLP-1 drugs as hernia prehabilitation exists.
When this study was published
Published in 2025 in Biomedicines.
The bigger picture
GLP-1 drugs are reshaping perioperative medicine. As more obese patients arrive for surgery already on semaglutide or tirzepatide, surgeons, anesthesiologists, and bariatric medicine specialists must collaborate on timing, fasting protocols, and surgical planning.
Questions still open
- How many days before hernia surgery should GLP-1 drugs be stopped to minimize aspiration risk?
- Does preoperative weight loss with GLP-1 drugs actually reduce hernia recurrence rates?
- Which patients benefit most from combined metabolic plus mechanical prehabilitation?
Common questions
Why do GLP-1 drugs cause aspiration risk during surgery?
Should I stop taking semaglutide before hernia surgery?
Read the original research
Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods.
Biomedicines, 13(12)
Citation
Paduraru, Dan Nicolae; Palcau, Alexandru Cosmin; Ion, Daniel; Seicaru, Razvan. (2025). Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods.. Biomedicines, 13(12). https://doi.org/10.3390/biomedicines13123117